<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547325</url>
  </required_header>
  <id_info>
    <org_study_id>2008-DOX-NT/005</org_study_id>
    <nct_id>NCT01547325</nct_id>
  </id_info>
  <brief_title>Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds</brief_title>
  <official_title>Double-Blind, Single-Site, Pilot Study of NanoDOX Hydrogel Versus Placebo Hydrogel for Dehisced Surgical Wounds.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoSHIFT LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>NanoSHIFT LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of NanoDOX Hydrogel versus Placebo
      Hydrogel on Dehisced Surgical Wounds.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of 100% wound closure during the 8-week study</measure>
    <time_frame>subjects will be followed during their participation in the study for an average of 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>subjects will be followed during their participatoni in the study for an average of 8 weeks</time_frame>
    <description>determined by wound score, area of the wound, and the assessment of wound effluent cytokine, chemokine, protease, and patient reported pain and quality of life questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dehisced Surgical Wounds</condition>
  <arm_group>
    <arm_group_label>NanoDOX Hydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Hydrogel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanoDOX 1% doxycycline monohydrate Hydrogel</intervention_name>
    <description>1% doxycycline monohydrate hydrogel</description>
    <arm_group_label>NanoDOX Hydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo hydrogel</intervention_name>
    <description>placebo hydrogel</description>
    <arm_group_label>Placebo Hydrogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 18 years of age or older

          -  Women of childbearing potential must have a negative urine pregnancy test at screening
             and at baseline, and:

          -  Agree to use a double-barrier method of contraception during their participation in
             this study;

               -  condoms (with spermicide) and hormonal contraceptives OR

               -  condoms (with spermicide) and intrauterine device OR

               -  intrauterine device and hormonal contraceptives OR

               -  Abstains from sexual intercourse during their participation in this study OR

               -  Is with a same-sex partner and does not participate in bisexual activities where
                  there is a risk of becoming pregnant

          -  Have a full-thickness dehisced surgical wound that is between 1.2cm2 and 4 cm2 at
             initial screening

          -  Be able to apply study drug to their wound, or have a reliable and capable caregiver
             do it

          -  Subjects will have adequate blood flow to the wound as defined by transcutaneous
             oxygen tension (TcpO2) of &gt;30mmHg recorded over intact epidermis at the dehisced
             surgical wound margin

          -  Non-infected (Quantitative bacterial count of &lt; 1.0 x 105 cfu)

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Pregnant or lactating woman or a female of childbearing potential who is not
             practicing acceptable form of birth control

          -  Allergic to tetracycline, minocycline, demeclocycline, or any other known tetracycline
             derivative

          -  Tested positive for a doxycycline-resistant infection

          -  Have undergone treatment with system corticosteroid or immunosuppressive therapy in
             the past 2 months

          -  Currently undergoing dialysis for renal failure

          -  Have participated in another clinical research trial within the last 30 days

          -  Subject has wounds resulting from any cause other than surgical intervention
             (diabetes, electrical burn, arterial insufficiency, chemical or radiation insult)

          -  Active or previous (within 60 days prior to the study screening visit) chemotherapy

          -  Active or previous (within 60 days prior to the study screening visit) radiation to
             the affected wound area to be treated by investigational drug or placebo

          -  Physical or mental disability or geographical concerns (residence not within
             reasonable travel distance) that would hamper compliance with required study visits

          -  The Investigator believes that the subject will be unwilling or unable to comply with
             study protocol requirements standard-of-care self-care requirements, and all
             study-related follow up visit requirements

          -  History of sickle cell anemia

          -  History of infection with Human Immunodeficiency Virus

          -  History of other immunodeficiency disorders

          -  Severe anemia - Hgb &lt; 10 g/dL (males) or &lt; 9 g/dL (females)

          -  Severe malnutrition (Albumin &lt; 3.0 gm/dl; &gt; 10% weight loss in preceding 6 weeks)

          -  Subjects that the Investigators deems unstable and/or require intensive monitoring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

